ΑΝΤΑΓΩΝΙΣΤΕΣ ΝΡΥΥ5

Η παρούσα εφεύρεση παρέχει φαρμακευτική σύνθεση για χρήση ως ανταγωνιστή υποδοχέα ΝΡΥ Υ5 που περιλαμβάνει μια ένωση του τύπου (Ι): όπου Neuropeptide Y5 receptor antagonist comprises new or known aminosulfinyl or aminosulfonyl derivatives (I). Neuropeptide Y5 receptor antagonist comprises aminosulfin...

Full description

Saved in:
Bibliographic Details
Main Authors TAKENAKA HIDEYUKI, KAWANISHI YASUYUKI, HANASAKI KOHJI, OKADA TETSUO
Format Patent
LanguageGreek
Published 09.04.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Η παρούσα εφεύρεση παρέχει φαρμακευτική σύνθεση για χρήση ως ανταγωνιστή υποδοχέα ΝΡΥ Υ5 που περιλαμβάνει μια ένωση του τύπου (Ι): όπου Neuropeptide Y5 receptor antagonist comprises new or known aminosulfinyl or aminosulfonyl derivatives (I). Neuropeptide Y5 receptor antagonist comprises aminosulfinyl or aminosulfonyl derivatives of formula (I), their prodrugs, salts or solvates. [Image] R 1optionally substituted lower alkyl, cycloalkyl or aryl, or R 1 + R 2lower alkylene; n : 1 or 2; X : (CR 3R 4) pA(CR 5R 6) q, HetU, NR 2X or optionally substituted lower alkylene, lower alkenylene, CO-lower alkylene or CO-lower alkenylene; A : optionally substituted cycloalkylene, cycloalkenylene, bicycloalkylene, arylene or divalent heterocycle; p, q : 0 or 1; Het : piperidinediyl, piperazinediyl, pyridinediyl, pyrazinediyl, pyrrolidinediyl or pyrrolediyl all attached to NR 2 via N; U : a bond, lower alkylene or lower alkenylene; Y : OCONR 7, CONR 7, CSNR 7, NR 7CO or NR 7CS; R 2-R 7H or lower alkyl; Z : optionally substituted lower alkyl, lower alkenyl, amino, lower alkoxy, carbocyclyl or heterocyclyl. Independent claims are also included for compounds (I), their salts, prodrugs and solvates in which: (i) X = 2-6C alkylene or 3-6C alkenylene; and R 1 = optionally substituted 3-10C alkyl or 5 or 6C cycloalkyl; provided that when Y = NR 7, the Z is not lower alkylphenylamino, lower hydroxyalkylphenylamino or acylphenylamino; (ii) A = heteroarylene or optionally substituted cycloalkylene, cycloalkenylene, bicycloalkylene or piperidinylene; and R 1 = optionally substituted 3-10C alkyl or 5 or 6C cycloalkyl; and (iii) A = p-phenylene; R 1 = 3-10C alkyl or 5 or 6C cycloalkyl and Z = p-lower alkylphenylene; provided that when R 1 = isopropyl, the Z is not p-n-butylphenylene. ACTIVITY : Anorectic; antidiabetic; hypotensive; antilipemic; antiarteriosclerotic; cardiant. MECHANISM OF ACTION : Neuropeptide-Y5 antagonist. In assays, a compound of formula (Ia) exhibited IC 50 values for neuropeptide Y5 binding of 0.1 nM and for cAMP in Chinese hamster ovary cells of 1.9 nM. [Image].
Bibliography:Application Number: CY20081101321T